WO2012091153A3 - Orally disintegrating tablet - Google Patents
Orally disintegrating tablet Download PDFInfo
- Publication number
- WO2012091153A3 WO2012091153A3 PCT/JP2011/080568 JP2011080568W WO2012091153A3 WO 2012091153 A3 WO2012091153 A3 WO 2012091153A3 JP 2011080568 W JP2011080568 W JP 2011080568W WO 2012091153 A3 WO2012091153 A3 WO 2012091153A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fine granules
- active ingredient
- pharmaceutically active
- lansoprazole
- controlled release
- Prior art date
Links
- 239000006191 orally-disintegrating tablet Substances 0.000 title abstract 3
- 239000008187 granular material Substances 0.000 abstract 8
- 239000004480 active ingredient Substances 0.000 abstract 6
- 229920001577 copolymer Polymers 0.000 abstract 4
- 238000013270 controlled release Methods 0.000 abstract 3
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 abstract 3
- 229960003174 lansoprazole Drugs 0.000 abstract 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 abstract 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 abstract 2
- 239000011247 coating layer Substances 0.000 abstract 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 abstract 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 abstract 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 abstract 1
- 229960003943 hypromellose Drugs 0.000 abstract 1
- 210000000214 mouth Anatomy 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112013014875A BR112013014875A2 (en) | 2010-12-27 | 2011-12-26 | orally disintegrating tablet |
CN2011800685821A CN103402500A (en) | 2010-12-27 | 2011-12-26 | Orally disintegrating tablet |
KR1020137019795A KR20140007364A (en) | 2010-12-27 | 2011-12-26 | Orally disintegrating tablet |
MX2013007588A MX2013007588A (en) | 2010-12-27 | 2011-12-26 | Orally disintegrating tablet. |
EA201390981A EA028217B1 (en) | 2010-12-27 | 2011-12-26 | Orally disintegrating tablet (variants) |
JP2013529237A JP2014501224A (en) | 2010-12-27 | 2011-12-26 | Orally disintegrating tablets |
CA2823166A CA2823166C (en) | 2010-12-27 | 2011-12-26 | Orally disintegrating tablet |
US13/997,862 US20130273157A1 (en) | 2010-12-27 | 2011-12-26 | Orally disintegrating tablet |
EP11811174.9A EP2658530A2 (en) | 2010-12-27 | 2011-12-26 | Orally disintegrating tablet |
AU2011350396A AU2011350396A1 (en) | 2010-12-27 | 2011-12-26 | Orally disintegrating tablet |
SG2013040944A SG190905A1 (en) | 2010-12-27 | 2011-12-26 | Orally disintegrating tablet |
TNP2013000220A TN2013000220A1 (en) | 2010-12-27 | 2013-05-24 | Orally disintegrating tablet |
ZA2013/04617A ZA201304617B (en) | 2010-12-27 | 2013-06-21 | Orally disintegrating tablet |
CR20130327A CR20130327A (en) | 2010-12-27 | 2013-06-27 | ORAL DISINTEGRATION COMPRESSED |
MA36063A MA34768B1 (en) | 2010-12-27 | 2013-06-28 | ORODISPERSIBLE TABLET |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061427384P | 2010-12-27 | 2010-12-27 | |
US61/427,384 | 2010-12-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012091153A2 WO2012091153A2 (en) | 2012-07-05 |
WO2012091153A3 true WO2012091153A3 (en) | 2012-09-07 |
Family
ID=45509604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/080568 WO2012091153A2 (en) | 2010-12-27 | 2011-12-26 | Orally disintegrating tablet |
Country Status (23)
Country | Link |
---|---|
US (1) | US20130273157A1 (en) |
EP (1) | EP2658530A2 (en) |
JP (1) | JP2014501224A (en) |
KR (1) | KR20140007364A (en) |
CN (1) | CN103402500A (en) |
AR (1) | AR084610A1 (en) |
AU (1) | AU2011350396A1 (en) |
BR (1) | BR112013014875A2 (en) |
CA (1) | CA2823166C (en) |
CL (1) | CL2013001793A1 (en) |
CO (1) | CO6731132A2 (en) |
CR (1) | CR20130327A (en) |
EA (1) | EA028217B1 (en) |
EC (1) | ECSP13012718A (en) |
MA (1) | MA34768B1 (en) |
MX (1) | MX2013007588A (en) |
PE (1) | PE20141115A1 (en) |
SG (2) | SG190905A1 (en) |
TN (1) | TN2013000220A1 (en) |
TW (1) | TW201304823A (en) |
UY (1) | UY33841A (en) |
WO (1) | WO2012091153A2 (en) |
ZA (1) | ZA201304617B (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9241910B2 (en) | 2008-03-11 | 2016-01-26 | Takeda Pharmaceutical Company Limited | Orally-disintegrating solid preparation |
ES2790358T3 (en) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Substituted Heteroaryl Aldehyde Compounds and Methods for Their Use in Increasing Tissue Oxygenation |
EP3141542B1 (en) | 2011-12-28 | 2020-05-27 | Global Blood Therapeutics, Inc. | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
GB201303781D0 (en) | 2013-03-04 | 2013-04-17 | Gauthier Pierre Pascal | Oral timer device and method of using same |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
MX2015011448A (en) | 2013-03-15 | 2016-06-06 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin. |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
ES2852054T3 (en) | 2013-03-15 | 2021-09-10 | Global Blood Therapeutics Inc | Compounds and their uses for modulation of hemoglobin |
SG11201507453VA (en) | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
EA202092627A1 (en) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION |
EP3868745A1 (en) | 2014-02-07 | 2021-08-25 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
CN111704543A (en) | 2014-11-14 | 2020-09-25 | 燿石治疗公司 | Process and intermediates for preparing alpha, omega-dicarboxylic acid terminated dialkyl ethers |
EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
WO2017096230A1 (en) | 2015-12-04 | 2017-06-08 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
TWI663160B (en) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
TWI778983B (en) * | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
WO2018209257A1 (en) * | 2017-05-11 | 2018-11-15 | Gemphire Therapeutics Inc. | Gemcabene compositions and methods of use thereof |
MX2020000332A (en) | 2017-07-10 | 2020-07-13 | Takeda Pharmaceuticals Co | Preparation comprising vonoprazan. |
CN108576205B (en) * | 2018-03-22 | 2022-01-04 | 湖北省农业科学院农产品加工与核农技术研究所 | Processing method for strawberry combined drying |
EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050214372A1 (en) * | 2004-03-03 | 2005-09-29 | Simona Di Capua | Stable pharmaceutical composition comprising an acid labile drug |
US20070141151A1 (en) * | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
WO2007078271A2 (en) * | 2005-12-20 | 2007-07-12 | Teva Pharmaceutical Industries Ltd. | Lansoprazole orally disintegrating tablets |
EP1837016A2 (en) * | 2006-03-08 | 2007-09-26 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical multiple-unit composition |
EP2098250A1 (en) * | 2006-12-28 | 2009-09-09 | Takeda Pharmaceutical Company Limited | Orally disintegrating solid preparation |
WO2009113703A2 (en) * | 2008-03-11 | 2009-09-17 | Takeda Pharmaceutical Company Limited | Orally-disintegrating solid preparation |
US20100015239A1 (en) * | 2008-07-17 | 2010-01-21 | Ahmed Salah U | Orally Disintegrating Solid Pharmaceutical Dosage Forms Comprising Delayed-Release Lansoprazole and Methods of Making and Using the Same |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6150978A (en) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | Pyridine derivative and preparation thereof |
JPH072761B2 (en) | 1985-03-20 | 1995-01-18 | 不二パウダル株式会社 | Microcrystalline cellulose spherical granules and method for producing the same |
JPS62277322A (en) | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | Stabilized pharmaceutical composition and production thereof |
FR2679451B1 (en) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | MULTIPARTICLE TABLET WITH RAPID DELIVERY. |
DE69331839T2 (en) | 1992-01-29 | 2002-12-12 | Takeda Chemical Industries, Ltd. | Fast-dissolving tablet and its manufacture |
JP2919771B2 (en) | 1995-04-17 | 1999-07-19 | 佐藤製薬株式会社 | Method for producing fast-dissolving tablet and fast-dissolving tablet produced by the method |
JPH0948726A (en) | 1995-08-07 | 1997-02-18 | Tanabe Seiyaku Co Ltd | Rapidly disintegrating preparation in mouth cavity and its production |
TW385306B (en) | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
JP3828648B2 (en) | 1996-11-14 | 2006-10-04 | 武田薬品工業株式会社 | Crystal of 2- (2-pyridylmethylsulfinyl) benzimidazole compound and process for producing the same |
CA2323680C (en) | 1998-05-18 | 2007-05-22 | Takeda Chemical Industries, Ltd. | Orally disintegrable tablets |
US7399485B1 (en) | 1998-07-28 | 2008-07-15 | Takeda Pharmaceutical Company Limited | Rapidly Disintegrable solid preparation |
TWI289557B (en) | 1999-06-17 | 2007-11-11 | Takeda Chemical Industries Ltd | A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
EP1277752B1 (en) | 2000-04-28 | 2006-11-22 | Takeda Pharmaceutical Company Limited | Process for producing optically active sulfoxide derivative |
DK1293507T3 (en) | 2000-05-15 | 2007-12-27 | Takeda Pharmaceutical | Process for producing crystals |
DK1337525T3 (en) | 2000-12-01 | 2011-09-19 | Takeda Pharmaceutical | Process for crystallizing (R) - or (S) -lansoprazole |
JP4493970B2 (en) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | Sustained formulation |
-
2011
- 2011-12-26 MX MX2013007588A patent/MX2013007588A/en not_active Application Discontinuation
- 2011-12-26 EA EA201390981A patent/EA028217B1/en not_active IP Right Cessation
- 2011-12-26 SG SG2013040944A patent/SG190905A1/en unknown
- 2011-12-26 TW TW100148775A patent/TW201304823A/en unknown
- 2011-12-26 JP JP2013529237A patent/JP2014501224A/en active Pending
- 2011-12-26 WO PCT/JP2011/080568 patent/WO2012091153A2/en active Application Filing
- 2011-12-26 BR BR112013014875A patent/BR112013014875A2/en active Search and Examination
- 2011-12-26 PE PE2013001471A patent/PE20141115A1/en not_active Application Discontinuation
- 2011-12-26 AU AU2011350396A patent/AU2011350396A1/en not_active Abandoned
- 2011-12-26 UY UY0001033841A patent/UY33841A/en not_active Application Discontinuation
- 2011-12-26 CA CA2823166A patent/CA2823166C/en active Active
- 2011-12-26 EP EP11811174.9A patent/EP2658530A2/en not_active Withdrawn
- 2011-12-26 SG SG10201602311XA patent/SG10201602311XA/en unknown
- 2011-12-26 US US13/997,862 patent/US20130273157A1/en not_active Abandoned
- 2011-12-26 CN CN2011800685821A patent/CN103402500A/en active Pending
- 2011-12-26 KR KR1020137019795A patent/KR20140007364A/en not_active Application Discontinuation
- 2011-12-27 AR ARP110104955A patent/AR084610A1/en unknown
-
2013
- 2013-05-24 TN TNP2013000220A patent/TN2013000220A1/en unknown
- 2013-06-19 CL CL2013001793A patent/CL2013001793A1/en unknown
- 2013-06-21 ZA ZA2013/04617A patent/ZA201304617B/en unknown
- 2013-06-25 EC ECSP13012718 patent/ECSP13012718A/en unknown
- 2013-06-27 CR CR20130327A patent/CR20130327A/en not_active Application Discontinuation
- 2013-06-28 MA MA36063A patent/MA34768B1/en unknown
- 2013-07-25 CO CO13176405A patent/CO6731132A2/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050214372A1 (en) * | 2004-03-03 | 2005-09-29 | Simona Di Capua | Stable pharmaceutical composition comprising an acid labile drug |
US20070141151A1 (en) * | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
WO2007078271A2 (en) * | 2005-12-20 | 2007-07-12 | Teva Pharmaceutical Industries Ltd. | Lansoprazole orally disintegrating tablets |
EP1837016A2 (en) * | 2006-03-08 | 2007-09-26 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical multiple-unit composition |
EP2098250A1 (en) * | 2006-12-28 | 2009-09-09 | Takeda Pharmaceutical Company Limited | Orally disintegrating solid preparation |
WO2009113703A2 (en) * | 2008-03-11 | 2009-09-17 | Takeda Pharmaceutical Company Limited | Orally-disintegrating solid preparation |
US20100015239A1 (en) * | 2008-07-17 | 2010-01-21 | Ahmed Salah U | Orally Disintegrating Solid Pharmaceutical Dosage Forms Comprising Delayed-Release Lansoprazole and Methods of Making and Using the Same |
Non-Patent Citations (5)
Title |
---|
EVONIK INDUSTRIES: "EUDRAGIT FS 30 D", 31 July 2010 (2010-07-31), pages 1 - 3, XP055028678, Retrieved from the Internet <URL:http://web.archive.org/web/20100731192517/http://eudragit.evonik.com/product/eudragit/en/products-services/eudragit-products/enteric-formulations/fs-30-d/Pages/default.aspx> [retrieved on 20120531] * |
FLORENCE LECOMTE ET AL: "pH-Sensitive Polymer Blends Used as Coating Materials to Control Drug Release from Spherical Beads: Elucidation of the Underlying Mass Transport Mechanisms", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 22, no. 7, 1 July 2005 (2005-07-01), pages 1129 - 1141, XP019370885, ISSN: 1573-904X, DOI: 10.1007/S11095-005-5421-2 * |
SCHMID S ET AL: "ENTERIC COATING OF IBUPROFEN CRYSTALS USING MODIFIED METHACRYLATE COPOLYMERS", DRUGS MADE IN GERMANY, AULENDORF, DE, vol. 44, no. 1, 1 January 2001 (2001-01-01), pages 12 - 19, XP001016138, ISSN: 0012-6682 * |
SHIMIZU T ET AL: "FORMULATION STUDY FOR LANSOPRAZOLE FAST-DISINTEGRATING TABLET. II. EFFECT OF TRIETHYL CITRATE ON THE QUALITY OF THE PRODUCTS", CHEMICAL & PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 51, no. 9, 1 October 2003 (2003-10-01), pages 1029 - 1035, XP001174705, ISSN: 0009-2363, DOI: 10.1248/CPB.51.1029 * |
WAGNER K G ET AL: "Development of disintegrating multiple-unit tablets on a high-speed rotary tablet press", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 50, no. 2, 1 September 2000 (2000-09-01), pages 285 - 292, XP004257203, ISSN: 0939-6411, DOI: 10.1016/S0939-6411(00)00078-3 * |
Also Published As
Publication number | Publication date |
---|---|
TN2013000220A1 (en) | 2014-11-10 |
CL2013001793A1 (en) | 2013-12-06 |
MX2013007588A (en) | 2013-08-09 |
AR084610A1 (en) | 2013-05-29 |
BR112013014875A2 (en) | 2016-10-18 |
SG190905A1 (en) | 2013-07-31 |
EP2658530A2 (en) | 2013-11-06 |
AU2011350396A1 (en) | 2013-07-11 |
EA028217B1 (en) | 2017-10-31 |
CN103402500A (en) | 2013-11-20 |
JP2014501224A (en) | 2014-01-20 |
CA2823166C (en) | 2019-04-09 |
MA34768B1 (en) | 2013-12-03 |
CA2823166A1 (en) | 2012-07-05 |
CO6731132A2 (en) | 2013-08-15 |
US20130273157A1 (en) | 2013-10-17 |
UY33841A (en) | 2012-07-31 |
KR20140007364A (en) | 2014-01-17 |
PE20141115A1 (en) | 2014-09-12 |
TW201304823A (en) | 2013-02-01 |
EA201390981A1 (en) | 2014-07-30 |
ZA201304617B (en) | 2014-08-27 |
CR20130327A (en) | 2013-08-22 |
WO2012091153A2 (en) | 2012-07-05 |
ECSP13012718A (en) | 2013-12-31 |
SG10201602311XA (en) | 2016-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012091153A3 (en) | Orally disintegrating tablet | |
MX2022002952A (en) | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phen oxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]- 4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile. | |
RU2337687C2 (en) | Pharmaceutical composition of controlled release and method of production thereof | |
JP2010270128A5 (en) | ||
JP2019147832A5 (en) | ||
CA2797812A1 (en) | Enteric tablet | |
NZ591688A (en) | Dosage form comprising time-pulsatile release beads | |
RU2015110824A (en) | PHARMACEUTICAL OR NUTRICEVITIC COMPOSITION WITH SLOW DELIVERY AND RESISTANCE TO ETHANOL | |
JP2013522219A5 (en) | ||
WO2006049564A8 (en) | New modified release pellet formulations for proton pump inhibitors | |
JP2012518655A5 (en) | ||
RU2015110825A (en) | RESISTANT TO ACTION OF THE GASTRIC JUICE PHARMACEUTICAL OR NUTRICEUTIC COMPOSITION RESISTANT TO THE INFLUENCE OF ETHANOL | |
AU2007276874A1 (en) | Granular pharmaceutical compositions | |
MX2007004987A (en) | New modified release tablet formulations for proton pump inhibitors. | |
RU2014131238A (en) | COMPOSITION WITH DELAYED RELEASE TO REDUCE THE URINE FREQUENCY AND METHOD OF ITS APPLICATION | |
JP2017537168A5 (en) | ||
RU2012136839A (en) | COMPOSITIONS FOR CARE OF THE ORAL CAVITY AND REMOVAL OF AN UNFAMING ODOR | |
CN103338774A (en) | Orally disintegrating tablet | |
JP2014533656A5 (en) | ||
JP2013529637A5 (en) | ||
EP2641594B1 (en) | Enteric coated solid pharmaceutical compositions for proton pump inhibitors | |
WO2014086857A1 (en) | Oral pharmaceutical composition comprising dabigatran etexilate | |
CA2797809A1 (en) | Enteric tablet | |
CA2733299A1 (en) | Oral pharmaceutical formulation for omeprazole comprising a specific separation layer | |
CN103751137A (en) | Multi-cell ranolazine slow-release pellet tablet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11811174 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 226590 Country of ref document: IL |
|
REEP | Request for entry into the european phase |
Ref document number: 2011811174 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011811174 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 0184013 Country of ref document: KE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013001793 Country of ref document: CL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13997862 Country of ref document: US Ref document number: 001471-2013 Country of ref document: PE |
|
ENP | Entry into the national phase |
Ref document number: 2823166 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12013501391 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2013529237 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/007588 Country of ref document: MX Ref document number: CR2013-000327 Country of ref document: CR |
|
ENP | Entry into the national phase |
Ref document number: 2011350396 Country of ref document: AU Date of ref document: 20111226 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13173 Country of ref document: GE |
|
ENP | Entry into the national phase |
Ref document number: 20137019795 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13176405 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201309398 Country of ref document: UA Ref document number: 201390981 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013014875 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013014875 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130613 |